2022
Patient-Level Analysis of Watchman Left Atrial Appendage Occlusion in Practice Versus Clinical Trials
Friedman DJ, Du C, Wang Y, Agarwal V, Varosy PD, Masoudi FA, Holmes DR, Reddy VY, Price MJ, Curtis JP, Freeman JV. Patient-Level Analysis of Watchman Left Atrial Appendage Occlusion in Practice Versus Clinical Trials. JACC Cardiovascular Interventions 2022, 15: 950-961. PMID: 35512918, PMCID: PMC9370831, DOI: 10.1016/j.jcin.2022.02.029.Peer-Reviewed Original ResearchConceptsRegistry patientsHemorrhagic stroke riskIschemic strokeWarfarin patientsTrial patientsStroke riskLAAO patientsClinical practiceMore pericardial effusionsPeriprocedural ischemic strokePropensity-matched analysisAtrial appendage occlusionCox proportional hazardsPatient-level dataFine-Gray modelMore comorbiditiesPROTECT AFNoncardiovascular deathPericardial effusionHemorrhagic strokeAppendage occlusionDevice implantationTrial criteriaClinical trialsSimilar risk
2021
Estimation of DAPT Study Treatment Effects in Contemporary Clinical Practice: Findings From the EXTEND-DAPT Study
Butala NM, Faridi KF, Tamez H, Strom JB, Song Y, Shen C, Secemsky EA, Mauri L, Kereiakes DJ, Curtis JP, Gibson CM, Yeh RW. Estimation of DAPT Study Treatment Effects in Contemporary Clinical Practice: Findings From the EXTEND-DAPT Study. Circulation 2021, 145: 97-106. PMID: 34743530, PMCID: PMC8748407, DOI: 10.1161/circulationaha.121.056878.Peer-Reviewed Original ResearchConceptsContemporary clinical practiceStent-treated patientsPercutaneous coronary interventionDAPT studyProlonged DAPTClinical practiceCoronary interventionMyocardial infarctionNational Cardiovascular Data Registry CathPCI RegistryTreatment effectsTrial resultsAttenuation of benefitLonger-duration DAPTMonths of DAPTProlonged DAPT durationDrug-eluting stentsCoronary stent proceduresModern clinical practiceGreater bleedingMore comorbiditiesRegistry patientsAntiplatelet therapyCerebrovascular eventsDAPT durationMore contemporary cohorts
2019
DURATION OF ANTIPLATELET THERAPY AFTER PERCUTANEOUS CORONARY INTERVENTION IN PATIENTS ON ORAL ANTICOAGULANTS IN CLINICAL PRACTICE
Tobolski J, Abbott J, Kolte D, Curtis J, Hira R, Wang Y, Minges K. DURATION OF ANTIPLATELET THERAPY AFTER PERCUTANEOUS CORONARY INTERVENTION IN PATIENTS ON ORAL ANTICOAGULANTS IN CLINICAL PRACTICE. Journal Of The American College Of Cardiology 2019, 73: 1081. DOI: 10.1016/s0735-1097(19)31688-2.Peer-Reviewed Original Research
2013
QRS Duration, Bundle-Branch Block Morphology, and Outcomes Among Older Patients With Heart Failure Receiving Cardiac Resynchronization Therapy
Peterson PN, Greiner MA, Qualls LG, Al-Khatib SM, Curtis JP, Fonarow GC, Hammill SC, Heidenreich PA, Hammill BG, Piccini JP, Hernandez AF, Curtis LH, Masoudi FA. QRS Duration, Bundle-Branch Block Morphology, and Outcomes Among Older Patients With Heart Failure Receiving Cardiac Resynchronization Therapy. JAMA 2013, 310: 617-626. PMID: 23942680, DOI: 10.1001/jama.2013.8641.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsAgedAged, 80 and overBundle-Branch BlockCardiac Resynchronization TherapyCardiac Resynchronization Therapy DevicesCardiovascular DiseasesCohort StudiesElectrocardiographyFee-for-Service PlansFemaleHeart FailureHumansMaleMedicarePatient ReadmissionRetrospective StudiesRiskTreatment OutcomeUnited StatesConceptsLeft bundle branch blockCRT-D implantationCardiac resynchronization therapyHeart failure readmissionQRS durationCause mortalityICD RegistryResynchronization therapyUnadjusted ratesMedicare beneficiariesNational Cardiovascular Data Registry ICD RegistryClinical practiceBundle branch block morphologyCause readmission rateRetrospective cohort studyLonger QRS durationBundle branch blockService Medicare beneficiariesCause readmissionCohort studyCRT-defibrillatorOlder patientsReadmission ratesHeart failureClinical trialsCenters for Cardiovascular Outcomes Research
Cook NL, Bonds DE, Kiefe CI, Curtis JP, Krumholz HM, Kressin NR, Peterson ED. Centers for Cardiovascular Outcomes Research. Circulation Cardiovascular Quality And Outcomes 2013, 6: 223-228. PMID: 23481526, PMCID: PMC3684990, DOI: 10.1161/circoutcomes.0b013e31828e8d5c.Peer-Reviewed Original ResearchMeSH KeywordsCardiovascular DiseasesContinuity of Patient CareCooperative BehaviorHealth Care ReformHealth Services ResearchHealthcare DisparitiesHumansInterdisciplinary CommunicationInterinstitutional RelationsMulticenter Studies as TopicNational Heart, Lung, and Blood Institute (U.S.)Organizational ObjectivesOutcome Assessment, Health CareProgram DevelopmentProgram EvaluationQuality Indicators, Health CareQuality of LifeTreatment OutcomeUnited StatesConceptsCardiovascular Outcomes ResearchOutcomes research programsBlood InstituteNational HeartCardiovascular conditionsCross-program collaborationOutcomes researchAcute coronary syndromeBetter patient outcomesQuality of lifeCoronary syndromeVenous thromboembolismClinical eventsCare transitionsPatient outcomesDisparate careEarly-stage investigatorsClinical practiceTranslational gapLungNational InstituteHealthcare deliveryOutcomesHeartCareSurvival of Patients Receiving a Primary Prevention Implantable Cardioverter-Defibrillator in Clinical Practice vs Clinical Trials
Al-Khatib SM, Hellkamp A, Bardy GH, Hammill S, Hall WJ, Mark DB, Anstrom KJ, Curtis J, Al-Khalidi H, Curtis LH, Heidenreich P, Peterson ED, Sanders G, Clapp-Channing N, Lee KL, Moss AJ. Survival of Patients Receiving a Primary Prevention Implantable Cardioverter-Defibrillator in Clinical Practice vs Clinical Trials. JAMA 2013, 309: 55-62. PMID: 23280225, PMCID: PMC3638257, DOI: 10.1001/jama.2012.157182.Peer-Reviewed Original ResearchConceptsPrimary prevention ICDsPrimary prevention clinical trialsTrial-eligible patientsSurvival of patientsPrevention clinical trialsClinical trialsICD RegistrySCD-HeFTClinical practiceRegistry patientsMADIT-IISimilar patientsNational Cardiovascular Data Registry ICD RegistryPrimary prevention implantable cardioverter defibrillatorsSurvival rateImplantable cardioverter-defibrillator therapyMADIT II criteriaMADIT II patientsSCD-HeFT criteriaCardioverter-defibrillator therapyClinical trial patientsLarge national registryRandomized clinical trialsProportional hazards modelImplantable cardioverter defibrillator
2012
Characteristics and Long-Term Outcomes of Percutaneous Revascularization of Unprotected Left Main Coronary Artery Stenosis in the United States A Report From the National Cardiovascular Data Registry, 2004 to 2008
Brennan JM, Dai D, Patel MR, Rao SV, Armstrong EJ, Messenger JC, Curtis JP, Shunk KA, Anstrom KJ, Eisenstein EL, Weintraub WS, Peterson ED, Douglas PS, Hillegass WB. Characteristics and Long-Term Outcomes of Percutaneous Revascularization of Unprotected Left Main Coronary Artery Stenosis in the United States A Report From the National Cardiovascular Data Registry, 2004 to 2008. Journal Of The American College Of Cardiology 2012, 59: 648-654. PMID: 22322080, DOI: 10.1016/j.jacc.2011.10.883.Peer-Reviewed Original ResearchConceptsULMCA percutaneous coronary interventionPercutaneous coronary interventionMain coronary artery stenosisU.S. clinical practiceMajor adverse eventsCoronary artery stenosisAdverse eventsULMCA stenosisCoronary interventionHazard ratioArtery stenosisUnprotected left main coronary artery stenosisClinical practiceLeft main coronary artery stenosisComposite major adverse eventsUnited States A ReportPercutaneous coronary intervention registryHospital mortality rateCoronary Intervention RegistryLong-term outcomesHigh procedural riskBare metal stentsDrug-eluting stentsHospital mortalityPCI use
2011
Operator Experience and Carotid Stenting Outcomes in Medicare Beneficiaries
Nallamothu BK, Gurm HS, Ting HH, Goodney PP, Rogers MA, Curtis JP, Dimick JB, Bates ER, Krumholz HM, Birkmeyer JD. Operator Experience and Carotid Stenting Outcomes in Medicare Beneficiaries. JAMA 2011, 306: 1338-1343. PMID: 21954477, PMCID: PMC3208144, DOI: 10.1001/jama.2011.1357.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsAgedAged, 80 and overAtherosclerosisCarotid StenosisCenters for Medicare and Medicaid Services, U.S.Clinical CompetenceFee-for-Service PlansFemaleHospital MortalityHumansInsurance CoverageMaleMedicarePhysiciansQuality of Health CareRetrospective StudiesStentsStrokeTime FactorsTreatment OutcomeUnited StatesConceptsAnnual operator volumeCarotid stentingOperator volumeMedicare beneficiariesNational coverage decisionHigh riskOperator experienceStudy periodThirty-day mortalityEmbolic protection devicesHigh-volume operatorsLow-volume operatorsService Medicare beneficiariesLow annual volumeMultivariable adjustmentOlder patientsRate of failureClinical trialsCoverage decisionsObservational studyMAIN OUTCOMEPatientsClinical practiceStentingMore procedures
2007
Preventing tomorrow's sudden cardiac death today Part II: Translating sudden cardiac death risk assessment strategies into practice and policy
Sanders GD, Al-Khatib SM, Berliner E, Bigger JT, Buxton AE, Califf RM, Carlson M, Curtis AB, Curtis JP, Domanski M, Fain E, Gersh BJ, Gold MR, Goldberger J, Haghighi-Mood A, Hammill SC, Harder J, Healey J, Hlatky MA, Hohnloser SH, Lee KL, Mark DB, Mitchell B, Phurrough S, Prystowsky E, Smith JM, Stockbridge N, Temple R, conference F. Preventing tomorrow's sudden cardiac death today Part II: Translating sudden cardiac death risk assessment strategies into practice and policy. American Heart Journal 2007, 153: 951-959. PMID: 17540195, DOI: 10.1016/j.ahj.2007.03.002.Peer-Reviewed Original ResearchConceptsSudden cardiac deathCardiac deathClinical practicePrevention of SCDRisk assessment strategiesDuke Clinical Research InstituteClinical Research InstituteSCD preventionClinical cardiovascular medicineRisk stratificationHigh riskCurrent evidenceClinical strategiesDuke CenterCardiovascular medicineHealth policyPreventionFuture evidenceRiskDeathFurther testingGroup of individualsAssessment strategiesLevel of riskProfessional societiesImpact of the Food and Drug Administration’s Public Health Notification on the Adoption of Drug-Eluting Stents
Curtis JP, Cohen DJ, Jones PG, Bach RG, Spertus JA, Krumholz HM. Impact of the Food and Drug Administration’s Public Health Notification on the Adoption of Drug-Eluting Stents. The American Journal Of Cardiology 2007, 99: 1227-1229. PMID: 17478147, DOI: 10.1016/j.amjcard.2006.12.031.Peer-Reviewed Original ResearchConceptsPublic health notificationDrug-eluting stentsDES useDrug Administration Public Health NotificationsUse of DESDrug Administration NotificationProspective registryMyocardial infarctionDES safetyClinical practiceStudy periodStentsRelative decreaseTemporary effectInfarctionPatientsNotificationFoodRegistryDramatic increase